Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany

<h4>Background</h4> The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to preve...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Delphina Gomes, Andreas Beyerlein, Katharina Katz, Gabriele Hoelscher, Uta Nennstiel, Bernhard Liebl, Klaus Überla, Rüdiger von Kries
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6f82bbee4c6343d49c07c086397072dc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f82bbee4c6343d49c07c086397072dc
record_format	dspace
spelling	oai:doaj.org-article:6f82bbee4c6343d49c07c086397072dc2021-11-11T08:14:55ZIs the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany1932-6203https://doaj.org/article/6f82bbee4c6343d49c07c086397072dc2021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570490/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4> The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to prevent SARS-CoV-2 infection and severe outcomes in octo- and novo-generians in a German state setting. <h4>Methods and findings</h4> A prospective observational study of 708,187 persons aged ≥80 years living in Bavaria, Germany, was conducted between Jan 9 to Apr 11, 2021. We assessed the vaccine effectiveness (VE) for two doses of the BNT162b2 vaccine with respect to SARS-CoV-2 infection and related hospitalisations and mortality. Additionally, differences in VE by age groups ≥80 to ≤89 years and ≥90 years were studied. Analyses were adjusted by sex. By the end of follow-up, 63.8% of the Bavarian population ≥80 years had received one dose, and 52.7% two doses, of the BNT162b2 vaccine. Two doses of the BNT162b2 vaccine lowered the proportion of SARS-CoV-2 infections and related outcomes, resulting in VE estimates of 68.3% (95% confidence interval (CI) 65.5%, 70.9%) for infection, 73.2% (95% CI 65.3%, 79.3%) for hospitalisation, and 85.1% (95% CI 80.0%, 89.0%) for mortality. Sex differences in the risk of COVID-19 outcomes observed among unvaccinated persons disappeared after two BNT162b2 vaccine doses. Overall, the BNT162b2 vaccine was equally effective in octo- and novo-genarians. <h4>Conclusions</h4> Two doses of BioNTech-Pfizer’s BNT162b2 vaccine is highly effective against COVID-19 outcomes in elderly persons.Delphina GomesAndreas BeyerleinKatharina KatzGabriele HoelscherUta NennstielBernhard LieblKlaus ÜberlaRüdiger von KriesPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Delphina Gomes Andreas Beyerlein Katharina Katz Gabriele Hoelscher Uta Nennstiel Bernhard Liebl Klaus Überla Rüdiger von Kries Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
description	<h4>Background</h4> The efficacy of the BioNTech-Pfizer BNT162b2 vaccination in the elderly (≥80 years) could not be fully assessed in the BioNTech-Pfizer trial due to low numbers in this age group. We aimed to evaluate the effectiveness of the BioNTech-Pfizer (BNT162b2) vaccine to prevent SARS-CoV-2 infection and severe outcomes in octo- and novo-generians in a German state setting. <h4>Methods and findings</h4> A prospective observational study of 708,187 persons aged ≥80 years living in Bavaria, Germany, was conducted between Jan 9 to Apr 11, 2021. We assessed the vaccine effectiveness (VE) for two doses of the BNT162b2 vaccine with respect to SARS-CoV-2 infection and related hospitalisations and mortality. Additionally, differences in VE by age groups ≥80 to ≤89 years and ≥90 years were studied. Analyses were adjusted by sex. By the end of follow-up, 63.8% of the Bavarian population ≥80 years had received one dose, and 52.7% two doses, of the BNT162b2 vaccine. Two doses of the BNT162b2 vaccine lowered the proportion of SARS-CoV-2 infections and related outcomes, resulting in VE estimates of 68.3% (95% confidence interval (CI) 65.5%, 70.9%) for infection, 73.2% (95% CI 65.3%, 79.3%) for hospitalisation, and 85.1% (95% CI 80.0%, 89.0%) for mortality. Sex differences in the risk of COVID-19 outcomes observed among unvaccinated persons disappeared after two BNT162b2 vaccine doses. Overall, the BNT162b2 vaccine was equally effective in octo- and novo-genarians. <h4>Conclusions</h4> Two doses of BioNTech-Pfizer’s BNT162b2 vaccine is highly effective against COVID-19 outcomes in elderly persons.
format	article
author	Delphina Gomes Andreas Beyerlein Katharina Katz Gabriele Hoelscher Uta Nennstiel Bernhard Liebl Klaus Überla Rüdiger von Kries
author_facet	Delphina Gomes Andreas Beyerlein Katharina Katz Gabriele Hoelscher Uta Nennstiel Bernhard Liebl Klaus Überla Rüdiger von Kries
author_sort	Delphina Gomes
title	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
title_short	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
title_full	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
title_fullStr	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
title_full_unstemmed	Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
title_sort	is the bnt162b2 covid-19 vaccine effective in elderly populations? results from population data from bavaria, germany
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/6f82bbee4c6343d49c07c086397072dc
work_keys_str_mv	AT delphinagomes isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT andreasbeyerlein isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT katharinakatz isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT gabrielehoelscher isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT utanennstiel isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT bernhardliebl isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT klausuberla isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany AT rudigervonkries isthebnt162b2covid19vaccineeffectiveinelderlypopulationsresultsfrompopulationdatafrombavariagermany
_version_	1718439315624689664

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany

Ejemplares similares